The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Incubator/Accelerator | Alive

About Patch

Patch is a mobile chatbot, based on Artificial Intelligence and designed to provide and receive data on Clinical Trials.

Patch Headquarter Location

Italy

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Patch

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Patch is included in 1 Expert Collection, including Digital Health.

D

Digital Health

12,808 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Patch News

United States Transdermal Patch Market Report 2021-2026: Dosage, Price & Clinical Trials Insights - Technology Innovation and Increasing Acceptability Toward Patch Drug Delivery Methodology

Mar 30, 2021

March 30, 2021 06:28 ET Dublin, IRELAND US Transdermal Patch Market Opportunity Will Surpass USD 6 Billion In Next Few Years Driven By Technology Innovation And Increasing Acceptability Toward Patch Drug Delivery Methodology The US transdermal patch drug delivery market is associated with large number of major key players inclined towards developing transdermal patches for different diseases. In addition, continuous research and development strategies opted by the focused researchers towards adding novel techniques to it is also believed to be adding prominent drivers to the market. More Than 25 FDA Approved Patches Are Available In The US Market And More Than 40 Are In Clinical Trials There are numerous advantages that are observed within the therapy. Some of the application-based advantages associated with the therapy are: painless, non-invasive, convenient, release of desirable disease and many more. The ultimate exposure of the drug through transdermal patches is also leading to high rate of consumption of the drugs as well as extensive survival rate of the patients suffering from different types of diseases. The respective market for drug delivery is also witnessed to be dominating the other drug delivery markets that are present in the pharmaceutical industry for long period of time. It is estimated that for more than two or three decades from now, the respective market in the US will continue to dominate the entire pharmaceutical market in the world. Looking forward, the robust and strong clinical pipeline associated with the market at pre-clinical and clinical level for different diseases such as cancer and many more are estimated to yield more specific trends that are never observed in the pharmaceutical market at global level. The entire navigation of the US researchers towards the urgent need of an efficient drug delivery system and having a prominent non-invasive technique for eradicating the disease-causing cells from the body of the patient. As per the analysis done for the US transdermal patch market, it is believed that in the next few years, the US market will be identifying several drugs for different diseases that could be administered inside the body with the aid of transdermal patches, compared with early 2000's. US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026 Report Highlights: US Transdermal Patch Market Insight US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase Number of Patch In Clinical Trials: > 40 Patch Availability, Dosage & Price Analysis On 20 Patches Approved by FDA Marketed Transdermal Patch Clinical Insight: > 25 FDA Approved Patch Value Chain Analysis for US Transdermal Patch Market US Transdermal Patch Market Opportunity Assessment by Indication Key Topics Covered: 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 9. US Transdermal Patch Contract Manufacturing Organization (CMO) 10. Transdermal Patches for Cardiovascular Diseases - US Market Availability, Dosage & Price Analysis 10.1 Clonidine Transdermal Patch (Catapres-TTS) 10.2 Nitro Glycerin Transdermal Patch 10.2.1 Nitro-Dur 10.2.3 Generic Nitroglycerine Transdermal Patch 11. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage & Price Analysis 11.1 Fentanyl Transdermal Patch (Duragesic) 11.2 Buprenorphine Transdermal Patch (Butrans Patch) 12. Transdermal Patches for Neurological Disorders - US Market Availability, Dosage & Price Analysis 12.1 Selegiline Transdermal Patch (Emsam) 12.2 Scopolamine Transdermal Patch (Transderm-Scop) 12.3 Rivastigmine Transdermal Patch (Exelon) 12.4 Methylphenidate Transdermal Patch (Daytrana) 12.5 Asenapine Transdermal Patch (Secuado) 12.6 Rotigotine Transdermal Patch (Neupro) 13. Transdermal Patch in Hormonal Therapy - US Market Availability, Dosage & Price Analysis 13.1 Estradiol Transdermal Patch

  • What is Patch's latest funding round?

    Patch's latest funding round is Incubator/Accelerator.

  • Who are the investors of Patch?

    Investors of Patch include BioUpper.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.